March 16 (Reuters) - Helix Biopharma Corp HBP.TO :
* Helix Biopharma Corp. announces second quarter fiscal 2016
results
* Cash reserves as at January 31, 2016 insufficient to see
current research and development initiatives through to
completion
* Management considers securing additional funds, expected
to be through issuance of equity securities of company
* Q2 loss per share C$0.03
* Cash reserves as at Jan 31, 2016, are insufficient to meet
anticipated cash needs for working capital and capital
expenditures through next 12 months
Source text for Eikon:
Further company coverage: HBP.TO